• Users Online: 292
  • Print this page
  • Email this page


 
 
Table of Contents
LETTER TO EDITOR
Year : 2020  |  Volume : 3  |  Issue : 2  |  Page : 394-395

Metronomics: The next generation of multitargeted therapy


Department of Medical Oncology, Tata Memorial Centre; Homi Bhabha National Institute, Mumbai, Maharashtra, India

Date of Submission31-Mar-2020
Date of Decision01-Apr-2020
Date of Acceptance02-Apr-2020
Date of Web Publication19-Jun-2020

Correspondence Address:
Shripad Banavali
MD Director Academics Tata Memorial Centre, Mumbai, Maharashtra
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/CRST.CRST_106_20

Get Permissions


How to cite this article:
Banavali S, Patil V, Noronha V, Prabhash K. Metronomics: The next generation of multitargeted therapy. Cancer Res Stat Treat 2020;3:394-5

How to cite this URL:
Banavali S, Patil V, Noronha V, Prabhash K. Metronomics: The next generation of multitargeted therapy. Cancer Res Stat Treat [serial online] 2020 [cited 2020 Aug 14];3:394-5. Available from: http://www.crstonline.com/text.asp?2020/3/2/394/287197



We were delighted to read the article titled, “Oral etoposide and cyclophosphamide: A low-cost Palliative Metronomic Chemotherapy in advanced pediatric cancers” by Kumar et al.[1] and the accompanying editorial.[2] This study comprised a retrospective collection of data from 49 patients treated over a period of time with metronomic chemotherapy and has its limitations in the form of a heterogeneous treatment population and variable treatment schedules. Having obtained a median overall survival of 155 days with low toxicity, the authors have concluded that a combination of oral cyclophosphamide and etoposide is a convenient and economical regimen with acceptable response rates in the palliative setting. This is yet another article in the slowly increasing literature on the use of oral metronomic therapies (OMTs) for pediatric cancers.[3],[4]

However, as pointed out by us previously,[5] the regimen does not actually fit into the category of OMTs. By definition, metronomic therapy is “long-term administration of chemotherapeutic agents in a relatively low, minimally toxic dose, with no prolonged drug-free breaks.”[5] As reported in the paper, nearly half of the patients received drugs for 2 weeks with 2 weeks off. This means that the patients received no drugs for 50% of the time, which is a prolonged drug-free break. Furthermore, another limitation of this study is that the authors have clubbed all the tumors together. In this era of precision medicine, we know that the hallmarks of cancer as well as the pathways involved are different not only for different types of cancers, but also for their subtypes. Therefore, one would ideally require different combinations of OMTs for different tumors.[6]

A vital piece of information that this paper provides is that metronomic therapies can not only be useful in solid tumors, but also in hematological malignancies. One of the most successful treatments in oncology is the treatment of childhood acute lymphoblastic leukemia, which is a prime example of metronomic therapy, especially with the standard-risk and intermediate-risk protocols. Therefore, as Dr. Amegan-Aho mentions, we are not only “surviving on less,” we are thriving on less.[2]

With accumulating data, we have moved forward by combining metronomic chemotherapy with repurposed drugs labeled as “metronomics.”[6],[7] We have successfully repurposed drugs such as celecoxib, propranolol, metformin, and tamoxifen. An ideal and effective metronomic combination should have drugs that act on the tumor, drugs that modify the tumor microenvironment, and drugs that modulate immunity. Thus, “metronomics” can potentially become the next generation multi-targeted therapy. Recently, we have published that when used in the right combination, OMCTs can be very effective in patients with refractory/relapsed sarcomas.[8]

We conclude with a quote from Victor Hugo– “Nothing else in the world, not all the armies ……is so powerful as an idea whose time has come.” Now is the right time to conduct randomized, multicentric trials in this field and find out how best to use these cost-effective and infrastructure-sensitive therapies to our advantage.[9] Many of us must have used metronomic therapies during this crisis of the COVID-19 pandemic.[10],[11] Perhaps, collating and publishing these data would be a good start!

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.



 
  References Top

1.
Kumar K, Radhakrishnan V, Dhanushkodi M, Kalaiyarasi JP, Mehra N, Kumar AR, et al. Oral etoposide and cyclophosphamide: A low-cost palliative metronomic chemotherapy in advanced pediatric cancers. Cancer Res Stat Treat 2020;3:64-8.  Back to cited text no. 1
  [Full text]  
2.
Amegan-Aho KH. Surviving on less. Cancer Res Stat Treat 2020;3:87-8.  Back to cited text no. 2
  [Full text]  
3.
Bhuvan LP, Radhakrishnan V, Raja A, Ganesarajah S, Sagar TG. Outcomes in rhabdomyosarcoma: Experience from a tertiary cancer center in India. Cancer Res Stat Treat 2019;2:4-9.  Back to cited text no. 3
    
4.
Parambil BC, Ramanathan S. Improving outcomes in rhabdomyosarcoma – The way ahead. Cancer Res Stat Treat 2019;2:69-71.  Back to cited text no. 4
  [Full text]  
5.
Banavali S, Prabhash K, Patil V. Assessing metronomic chemotherapy for progressive pediatric solid malignant tumors. JAMA Oncol 2018;4:743-4.  Back to cited text no. 5
    
6.
André N, Banavali S, Snihur Y, Pasquier E. Time for metronomics in developing countries? Lancet Oncol 2013;14:e239-48.  Back to cited text no. 6
    
7.
Chandrasekharan A, Karunanithi S, Gangadharan KV. Metronomic chemotherapy and propranolol in a patient with metastatic angiosarcoma: Magic bullets? Cancer Res Stat Treat 2020;3:110-2.  Back to cited text no. 7
  [Full text]  
8.
Devadas SK, Banavali S. Retrospective analysis of outcomes of patients with relapsed, refractory and metastatic sarcomas who have received metronomic chemotherapy. Gulf J Oncol 2019;1:22-8.  Back to cited text no. 8
    
9.
Noronha V. Making a case for cancer research in India. Cancer Res Stat Treat 2018;1:71-4.  Back to cited text no. 9
  [Full text]  
10.
Saroha M, Moulik NR. COPING with CORONA: A developing country perspective on managing children with cancer during COVID-19 pandemic. Cancer Res Stat Treat 2020;3 Suppl S1:97-101.  Back to cited text no. 10
    
11.
Patil VM, Srikanth A, Noronha V, Joshi A, Dhumal S, Menon N, et al. The pattern of care in head-and-neck cancer: Comparison between before and during the COVID-19 pandemic. Cancer Res Stat Treat 2020;3 Suppl S1:7-12.  Back to cited text no. 11
    



This article has been cited by
1 Authorsę reply to Banavali et al., Bansal et al. and Viswanathan et al.
Kiran Kumar,Venkatraman Radhakrishnan
Cancer Research, Statistics, and Treatment. 2020; 3(2): 398
[Pubmed] | [DOI]



 

Top
 
  Search
 
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

 
  In this article
References

 Article Access Statistics
    Viewed99    
    Printed3    
    Emailed0    
    PDF Downloaded22    
    Comments [Add]    
    Cited by others 1    

Recommend this journal